Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer

European Urology

Volumn 62, Issue 6, 2012, Pages 1088-1096

  Yates, David R ^a   Brausi, Maurizio A ^b,j   Catto, James W F ^a   Dalbagni, Guido ^c   Rouprêt, Morgan ^d   Shariat, Shahrokh F ^e   Sylvester, Richard J ^f   Witjes, J Alfred ^g   Zlotta, Alexandre R ^h   Palou Redorta, Juan ⁱ  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b AUSL Modena   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^f EORTC DATA CENTER   (Belgium)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^j Nuovo Ospedale S Agostino   (Italy)

more..

Author keywords

Bacille Calmette Gu rin; BCG; Bladder cancer; Cystectomy; Intravesical therapy; Non muscle invasive; Urothelial carcinoma

Indexed keywords

ALPHA INTERFERON; AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; BCG VACCINE; CISPLATIN; DOCETAXEL; GEMCITABINE; HYALURONIC ACID; LENALIDOMIDE; MITOMYCIN; PACLITAXEL; SCH 721015; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CELL PROLIFERATION; CHEMORADIOTHERAPY; CHEMOTHERAPY; CLINICAL PROTOCOL; COCHRANE LIBRARY; CYSTECTOMY; DISEASE SPECIFIC SURVIVAL; DNA REPLICATION; DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG TREATMENT FAILURE; DYSURIA; ELECTROMOTIVE DRUG ADMINISTRATION; EMBASE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; MEDICAL HISTORY; MEDLINE; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PHOTODYNAMIC THERAPY; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE FREE SURVIVAL; RECURRENT CANCER; REVIEW; RISK BENEFIT ANALYSIS; SALVAGE THERAPY; SYSTEMATIC REVIEW; THERMOCHEMOTHERAPY; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; HUMANS; NEOPLASM INVASIVENESS; TREATMENT FAILURE; URINARY BLADDER NEOPLASMS;

EID: 84868518906     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.08.055     Document Type: Review

References (64)

1. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
2. M. Brausi, J.A. Witjes, and D. Lamm A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group J Urol 186 2011 2158 2167
3. F.M. Martin, and A.M. Kamat Definition and management of patients with bladder cancer who fail BCG therapy Expert Rev Anticancer Ther 9 2009 815 820
4. B.P. Schrier, M.P. Hollander, B.W.G. van Rhijn, L.A.L.M. Kiemeney, and J.A. Witjes Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy Eur Urol 45 2004 292 296
5. S. van den Bosch, and J.A. Witjes Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review Eur Urol 60 2011 493 500
6. H.W. Herr, and G. Dalbagni Defining bacillus Calmette-Guerin refractory superficial bladder tumors J Urol 169 2003 1706 1708
7. D. Lamm, M. Colombel, and R. Persad Clinical practice recommendations for the management of non-muscle-invasive bladder cancer Eur Urol Suppl 7 2008 651 666
8. A.M. Nieder, M. Brausi, and D. Lamm Management of stage T1 tumors of the bladder: International Consensus Panel Urology 66 Suppl 6A 2005 108 125
9. M.A. O'Donnell, and A. Boehle Treatment options for BCG failures World J Urol 24 2006 481 487
10. T.C.M. Zuiverloon, A.J.M. Nieuweboer, H. Vékony, W.J. Kirkels, C.H. Bangma, and E.C. Zwarthoff Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review Eur Urol 61 2012 128 145
11. R.J. Sylvester Combining a molecular profile with a clinical and pathological profile: biostatistical considerations Scand J Urol Nephrol Suppl 2008 185 190
12. J. Fernandez-Gomez, E. Solsona, and M. Unda Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials Eur Urol 53 2008 992 1002
13. F.N. Joudi, B.J. Smith, M.A. O'Donnell, and B.R. Konety The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy J Urol 175 2006 1634 1639 discussion 1639-40
14. J. Palou, R.J. Sylvester, and O. Rodríguez Faba Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin Eur Urol 62 2012 118 125
15. M.J. Resnick, M. Bergey, L. Magerfleisch, J.E. Tomaszewski, S.B. Malkowicz, and T.J. Guzzo Longituidinal evaluation of the concordance and prognostic value of lymphovascular invasion in transurethral resection and radical cystectomy specimens BJU Int 107 2011 46 52
16. E. Solsona, I. Iborra, R. Dumont, J. Rubio-Briones, J. Casanova, and S. Almenar The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer J Urol 164 2000 685 689
17. B.W.G. van Rhijn, T.H. van der Kwast, and S.S. Alkhateeb A new and highly prognostic system to discern T1 bladder cancer substage Eur Urol 61 2012 378 384
18. B.L. Gallagher, F.N. Joudi, J.L. Maymi, and M.A. O'Donnell Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy Urology 71 2008 297 301
19. H.M. Rosevear, A.J. Lightfoot, K.K. Birusingh, J.L. Maymi, K.G. Nepple, and M.A. O'Donnell Factors affecting response to bacillus Calmette-Guerin plus interferon for urothelial carcinoma in situ J Urol 186 2011 817 823
20. C.L. Amling, J.B. Thrasher, H.A. Frazier, R.K. Dodge, J.E. Robertson, and D.F. Paulson Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder J Urol 151 1994 31 35 discussion 35-6
21. F.J. Bianco Jr., D. Justa, D.J. Grignon, W.A. Sakr, J.E. Pontes, and D.P. Wood Jr. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy Urol Oncol 22 2004 290 294
22. R.E. Hautmann, B.G. Volkmer, and K. Gust Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1G3) World J Urol 27 2009 347 351
23. G.S. Kulkarni, A. Finelli, N.E. Fleshner, M.A. Jewett, S.R. Lopushinsky, and S.M. Alibhai Optimal management of high-risk T1G3 bladder cancer: a decision analysis PLoS Med 4 2007 e284
24. G.S. Kulkarni, S.M. Alibhai, and A. Finelli Cost-effectiveness analysis of immediate radical cystectomy versus intravesical bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer Cancer 115 2009 5450 5459
25. S.P. Lerner, C.M. Tangen, H. Sucharew, D. Wood, and E.D. Crawford Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer Urol Oncol 27 2009 155 159
26. H.W. Herr, and P.C. Sogani Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166 2001 1296 1299
27. G.N. Thalmann, R. Markwalder, O. Shahin, F.C. Burkhard, W.W. Hochreiter, and U.E. Studer Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 172 2004 70 75
28. S. Denzinger, H.M. Fritsche, W. Otto, A. Blana, W.F. Wieland, and M. Burger Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 53 2008 146 152
29. S.F. Shariat, P.I. Karakiewicz, and G.S. Palapattu Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium J Urol 176 2006 2414 2422 discussion 2422
30. A. Pycha, and E. Comploj The dilemma of cystectomy in old-old and oldest-old patients Expert Rev Anticancer Ther 11 2011 1863 1870
31. S.M. Donat, T. Siegrist, A. Cronin, C. Savage, M.I. Milowsky, and H.W. Herr Radical cystectomy in octogenarians - does morbidity outweigh the potential survival benefits? J Urol 183 2010 2171 2177
32. Novotny V, Zastrow S, Koch R, Wirth MP. Radical cystectomy in patients over 70 years of age: impact of comorbidity on perioperative morbidity and mortality. World J Urol. In press.
33. T.M. Morgan, K.A. Keegan, and D.A. Barocas Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy J Urol 186 2011 829 834
34. Horovitz D, Turker P, Bostrom PJ, et al. Does patient age affect survival after radical cystectomy? BJU Int. In press.
35. H.M. Fritsche, M. Burger, and R.S. Svatek Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort Eur Urol 57 2010 300 309
36. F.N. Joudi, B.J. Smith, and M.A. O'Donnell Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer Urol Oncol 24 2006 344 348
37. G. Dalbagni, P. Russo, and J. Sheinfeld Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder J Clin Oncol 20 2002 3193 3198
38. G. Dalbagni, P. Russo, and B. Bochner Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder J Clin Oncol 24 2006 2729 2734
39. R. Bartoletti, T. Cai, and M. Gacci Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study Urology 66 2005 726 731
40. N.K. Mohanty, R.L. Nayak, P. Vasudeva, and R.P. Arora Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience Urol Oncol 26 2008 616 619
41. G. Di Lorenzo, S. Perdona, and R. Damiano Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial Cancer 116 2010 1893 1900
42. R. Addeo, M. Caraglia, and S. Bellini Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance J Clin Oncol 28 2010 543 548
43. O.N. Gofrit, A. Shapiro, and D. Pode Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer Urology 63 2004 466 471
44. B. Moskovitz, G. Meyer, and A. Kravtzov Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients Ann Oncol 16 2005 585 589
45. J. Witjes, K. Hendricksen, O. Gofrit, O. Risi, and O. Nativ Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party World J Urol 27 2009 319 324
46. O. Nativ, J.A. Witjes, and K. Hendricksen Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin J Urol 182 2009 1313 1317
47. S. Halachmi, B. Moskovitz, and M. Maffezzini Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder Urol Oncol 29 2011 259 264
48. R.J.M. Lammers, J.A. Witjes, and B.A. Inman The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review Eur Urol 60 2011 81 93
49. J.M. McKiernan, P. Masson, and A.M. Murphy Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy J Clin Oncol 24 2006 3075 3080
50. M.A. Laudano, L.J. Barlow, and A.M. Murphy Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy Urology 75 2010 134 137
51. L.J. Barlow, J.M. McKiernan, and M.C. Benson The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience World J Urol 27 2009 331 335
52. C. Mugabe, Y. Matsui, and A.I. So In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer Clin Cancer Res 17 2011 2788 2798
53. Z. Lu, T.K. Yeh, and J. Wang Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy J Urol 185 2011 1478 1483
54. P.F. Bassi, A. Volpe, and D. D'Agostino Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder: results of a phase I study J Urol 185 2011 445 449
55. J.M. McKiernan, L.J. Barlow, M.A. Laudano, M.J. Mann, D.P. Petrylak, and M.C. Benson A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer J Urol 186 2011 448 451
56. B.N. Breyer, J.M. Whitson, P.R. Carroll, and B.R. Konety Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer Urol Oncol 28 2010 510 514
57. R. Waidelich, H. Stepp, R. Baumgartner, E. Weninger, A. Hofstetter, and M. Kriegmair Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer J Urol 165 2001 1904 1907
58. A.P. Berger, H. Steiner, A. Stenzl, T. Akkad, G. Bartsch, and L. Holtl Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study Urology 61 2003 338 341
59. M. Brausi, B. Campo, and G. Pizzocaro Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study Urology 51 1998 506 509
60. S.M. Di Stasi, A. Giannantoni, and R.L. Stephen Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study J Urol 170 2003 777 782
61. S.M. Di Stasi, A. Giannantoni, and A. Giurioli Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial Lancet Oncol 7 2006 43 51
62. S.M. Di Stasi, and C. Riedl Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer World J Urol 27 2009 325 330
63. S.J. Harland, H. Kynaston, and K. Grigor A randomised trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder J Urol 178 2007 807 813
64. C. Weiss, C. Wolze, and D.G. Engehausen Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol 24 2006 2318 2324